I have over 15 years of experience in Biotechnology and Synthetic Biology, with a strong focus on viral and non-viral vaccines, cell and gene therapies, and cutting-edge nucleic acid-based technologies. I hold a degree in Biotechnology, a PhD in Synthetic Biology, and I’m also a certified Clinical Laboratory Technician. Beyond that, I’ve completed postgraduate studies in Pharmaceutical Biotechnology and Synthetic Biology, alongside certificates in Bioinformatics, Immunoinformatics, Programming, and Graphic Design. Currently, I am pursuing a Master’s degree in Bioinformatics.
As the Founder and CEO of SYTE.bio, a Synthetic Biology company dedicated to advancing next-generation DNA and RNA-based vaccines and therapies for both human and veterinary medicine, I lead an exceptional team that is continually pushing the boundaries of innovation. My execution-oriented mindset has enabled us to achieve impressive results in a swift manner.
In addition to my role at SYTE.bio, I am also the CEO and Founder of Healix Instruments, a medical device company, and I previously served as the Interim Chief Scientific Officer for Athergen, a Boston-based firm specializing in cell reprogramming technology using miRNA. I have founded and lead BioConsulting Group, a global consulting firm, and also serve as a Strategic Consultant at BioStrategy Advisors LLC in Boston. Over the years, I’ve evaluated the scientific value of various technologies, guided R&D efforts from discovery through pre-clinical and clinical stages, and advised start-up founders on therapy and device development, AI integration, and pipeline prioritization.
My commitment to shaping the Synthetic Biology landscape extends beyond my businesses. I am the Founder and President of the Argentinean Synthetic Biology Association, the first organization of its kind in Latin America, and I teach Genetic Engineering at Universidad Favaloro in Argentina. My diverse background includes developing cancer treatments for melanoma and sarcoma using DNA, RNA, oncolytic viruses, and engineered viral platforms, as well as addressing diseases such as Type 1 and Type 2 Diabetes and anemia. I have also contributed to the development of vaccines for rabies, COVID, dengue, and hantavirus.
My expertise spans Biotechnology, Molecular Biology, Synthetic Biology, Genetic Engineering, Bioinformatics, and the development of viral and non-viral vaccines and gene therapies. I am skilled in patent analysis and writing, having been granted patents on groundbreaking technologies, and I’ve applied my knowledge to management, corporate strategy, business development, and creating strategic business agreements. My mission is to drive healthcare innovation by bringing transformative medical solutions to life and providing strategic advice that fosters the growth of biotechnology projects.
I have directed several bachelor’s theses in Biology, Biotechnology, and Bioinformatics, as well as Engineering theses in Electronics. This has involved leading the development of DNA & RNA Delivery Vehicles, diagnostic tools, electroporators for in vivo cell and tissue transfection, and bioinformatics algorithms for the in silico design of synthetic antigens.
Founder & CEO - SYTE.bio